Gmail is quietly killing off two features that have let users manage multiple email accounts from a single interface for over a decade. Starting this month, Gmail is discontinuing “Gmailify” and the ...

In the last two years, many enterprises measured “AI progress” the same way they measured software progress: how many tools were deployed and how many teams adopted them. That era is ending. A new ...

Senators Richard Blumenthal, Edward Markey, and Elizabeth Warren said they were "extremely troubled" by Amazon offering vehicles with unresolved recalls. In their December 22 letter, they warned that ...

Recursion Pharmaceuticals (RXRX) is upgraded to Buy, driven by promising REC-4881 data and analyst optimism for FAP market potential. REC-4881's Phase 1b/2 results show a 43% median polyp burden ...

When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...

Shares of clinical-stage biotechnology company Recursion Pharmaceuticals (NASDAQ: RXRX) soared 11.43% on Wednesday, significantly outperforming the broader market. The rally followed a major analyst ...

This post was updated Dec. 7 at 6:18 p.m. It was lightly raining when Ebony Moore – a customer relations agent at UCLA’s Trouble Call Desk – arrived at her office in the UCLA Facilities Management ...

First Brands Group’s bankruptcy advisers are facing a new challenge that could impact how a potential restructuring of the auto parts supplier is carried out. UMB Bank contends First Brands’ new ...

A screenshot showing the transportation data dashboard in Raleigh, N.C., where officials are experimenting with technologies like artificial intelligence, GIS and real-time video feeds to elevate ...